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ABSTRACT
Background There is a paucity of data on fertility or
pregnancy in patients with primary sclerosing cholangitis
(PSC).
Objective To assess fertility in PSC by comparing the
number of children in a large cohort of PSC patients to
healthy controls and to investigate the outcome of




Participants 229 PSC patients and 569 healthy controls
were evaluated for the number of children. 17 patients
with PSC and at least one pregnancy, or who received
a diagnosis of PSC within 6 months after delivery, were
included in the more detailed analysis.
Main outcome measures Number of children per
patient and control; disease activity during pregnancy
and after delivery including maternal complications; long-
term development of live births, fetal loss rate and the
influence of medication on fetal and maternal outcome.
Results Fertility did not seem to be reduced in PSC since
the number of children did not differ between PSC
patients and healthy controls. 25 pregnancies in 17
female PSC patients (median age at conception 31 years)
were investigated in detail. An increase in liver enzymes
was documented during five pregnancies (20%) and eight
times (32%) post-partum. There were no serious maternal
complications. All 21 live births presented with a normal
perinatal and postnatal development over a median
observation time of 50 months. Two pregnancies were
delivered pre-term and four fetal losses occurred early in
pregnancy (<12 wk). Continuation of treatment with
ursodeoxycholic acid (15/21) or azathioprine (2/21) had
no negative effects on pregnancy outcome.
Conclusions Fertility does not seem to be reduced in
patients with PSC, who are able to deliver healthy
children without an apparent increase in risk for mother
or child.
INTRODUCTION
Primary sclerosing cholangitis (PSC) is a chronic
inflammatory and fibrosing disease of intra- and/or
extrahepatic bile ducts leading to end-stage liver
disease or cholangiocarcinoma in 10e20 years.1 2
Since the onset of disease usually occurs before the
age of 40, many female patients with PSC will be of
child-bearing age. The desire to have a family
frequently raises questions about the outcome of
pregnancies including the associated risks for the
mother and the best treatment and surveillance
strategies.
Pregnancy may affect the course of autoimmune
and immune-mediated diseases such as systemic
lupus erythematosus and rheumatoid arthritis, as
well as autoimmune hepatitis (AIH) and primary
biliary cirrhosis.3e9 Although the aetiology of
PSC is still unknown, some characteristics such as
the strong association with inflammatory bowel
disease, HLA and other genetic associations, as well
as histological and serological findings, point to an
immune mediated, if not autoimmune pathogen-
esis.10 11 Therefore, the course of PSC may be
affected by pregnancy as well. To date, only a few
cases of pregnancy and PSC have been published
and there is no information about whether
the disease affects fertility.11e14 This renders the
counselling of young patients with PSC and the
care of patients with PSC and pregnancy difficult.
We here report the outcome of 25 pregnancies in
patients with PSC and the effect of pregnancy on
the disease course. In addition, the number of
children from parents with PSC was compared to
healthy controls in a large number of subjects in
order to assess a potential reduction of patient’s
fertility. Pregnancy did not seem to have a negative
impact on the short-term course of disease and,
overall, pregnancy outcomes were favourable.
Moreover, the number of children was not different
between patients with PSC and healthy controls.
See Commentary, p 1027
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Significance of this study
What is already known about this subject?
< Potential effects of primary sclerosing cholan-
gitis (PSC) on fertility are unknown.
< Few case reports have described pregnancy in
PSC with variable maternal and fetal outcomes.
What are the new findings?
< Fertility does not seem to be reduced in patients
with PSC as compared to healthy controls.
< Pregnancy in patients with PSC resulted in
a normal fetal outcome.
< Despite a frequent rise in serum liver tests, no
serious maternal complications were observed
during pregnancy or after delivery.
How might it impact on clinical practice in the
foreseeable future?
< PSC frequently presents in child-bearing age.
The study reported provides new data required
for the counselling and care of patients with PSC
and pregnancy.
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PATIENTS AND METHODS
The population-based recruitment of patients and controls for
the analysis of complex genotype-phenotype relationships
(PopGen) is a validated database that has been previously
described.15 For this study, the registry was queried for PSC
patients and data on gender, age, presence of inflammatory
bowel disease (IBD) and number of children. From the same
database, information on the number of children was obtained
from a healthy control group.
Patients diagnosed with PSC by generally accepted criteria1 2 16
were included in the detailed analysis if they became pregnant
after the diagnosis of PSC or if they had been diagnosed with
PSC within 6 months from delivery or pregnancy loss. The
records of female patients with PSC from the University Medical
Center Hamburg-Eppendorf identified 11 patients who fulfilled
the inclusion criteria. Three additional patients were included
from the liver units of the Universities of Munich and Mainz.
Three more patients could be identified by contacting the
German patient support group (AK PSC of the Deutsche Crohn
und Colitis Vereinigung, DCCV). Data was acquired retrospec-
tively from patient records and prospectively by questionnaires
addressing disease status at the time of pregnancy and pregnancy
outcome.
Adverse pregnancy outcome was defined as a spontaneous
pregnancy loss for which no obvious medical explanation was
present (eg, chromosomal aberrations) or a pre-term delivery
before the 36th week of gestation leading to perinatal death or
severe disability. A flare in disease activity was defined as a rise in
bilirubin, ALT or alkaline phosphatase to more than twofold of
the latest pre-pregnancy value or reappearance of typical
symptoms. Due to the natural rise in alkaline phosphatase levels
during the third trimester caused by the placenta and increased
maternal bone turnover,17 an isolated rise in alkaline phospha-
tase levels was not rated as an acute flare during that period of
pregnancy.
The study conformed to the guidelines of the 1975 Declara-
tion of Helsinki and was approved by the local ethics
committee. All patients gave written informed consent.
RESULTS
Number of children in PSC patients and healthy controls
We were first interested whether PSC results in reduced
fertility leading to a lower number of children per person as
compared to healthy controls. The number of children in 229
patients with PSC was compared to an age-matched healthy
control group (n¼569, table 1) from a prospectively acquired
data base. Fifty nine per cent of PSC patients had concomitant
inflammatory bowel disease. The number of children did not
differ between patients and controls and the presence of PSC
had no effect on the number of children per individual or the
rate of nulliparity as compared to healthy controls. Also, there
was no significant difference between men and women in the
PSC or control group with regard to the number of children or
the rate of nulliparity (tables 1 and 2). These data suggest that
fertility may not be reduced in patients with PSC. In multi-
variate logistic regression analysis, the presence or absence of
IBD had no influence on fertility of patients with PSC (data
not shown).
Analysis of pregnancy in PSCdpatient characteristics
Twenty-five pregnancies in 17 women with PSC could be
investigated in more detail. Patient characteristics are given in
table 3. The median age at diagnosis of PSC was 26 years (range
13e36) and the median age at conception was 31 years (range
22e37). One woman was diagnosed with PSC within 3 months
after delivery. Two patients had histologically proven compen-
sated liver cirrhosis at the time of pregnancy and concomitant
IBD was present in 14 patients. In two patients, overlap
syndrome with AIH had been diagnosed.
Maternal outcome
No serious adverse events were recorded in those patients with
known PSC at the time of conception (table 4). It was noted
that there were no complications in the two patients with
known liver cirrhosis. Disease activity was assessed by changes
in liver enzymes during pregnancy and after delivery. Data on
liver enzymes before, during and after pregnancy were available
in 20 of 21 live births. Details on the course of liver enzymes are
given in figure 1. In 20% of pregnancies an elevation of liver
enzymes above twice the pre-pregnancy value occurred during
pregnancy and in 32% after delivery. This led to treatment
modifications with an increased UDCA dose in two pregnancies.
However, enzyme activity returned to pre-pregnancy levels in
most patients within a few months after delivery.
Intrahepatic cholestasis of pregnancy (ICP) was suspected by
the consulting hepatologist to cause the rise in liver enzymes
within the third trimester in at least two pregnancies. In both of
these patients severe pruritus developed during the last trimester
as the primary clinical symptom. In one of the patients the
onset of mild pruritus was after the 16th week of gestation but
worsened severely in the last trimester. Of note, less severe
symptoms were also present in the first pregnancy during the
last trimester. There was no evidence of biliary obstruction or
dominant stenoses by ultrasound examination; total bilirubin
was in the upper normal range, the serum transaminases and g
glutamyl transpeptidase levels were up to threefold elevated. In
Table 1 Clinical characteristics and number of children from PSC
patients and healthy controls obtained from the PopGen database
PSC Healthy controls
n[229 n[569
n % n %
Female 86 38 233 41
With children 121 53 303 53
IBD 136 60 0 0
Ulcerative colitis 93 41 e e
Crohn’s disease 22 10 e e
Indeterminate colitis 21 9 e e
w/o IBD 89 39 e e
Unknown 4 2 e e
Mean SD Mean SD
Age (years) 44 13 42 13
Children/person 1.06 1.14 1.01 1.08
Children/sex
Females 1.16 0.981 0.91 1.062
Males 0.92 1.209 1.07 1.086
PSC, primary sclerosing cholangitis; IBD, inflammatory bowel disease.
Table 2 Factors influencing the presence or the number of children in
PSC patients or healthy controls
Presence of children Number of children
p 95% CI p 95% CI
PSC/control group 0.83 0.66 to 1.40 0.88 0.14 to 0.16
Gender 0.45 0.62 to 1.24 0.64 0.11 to 0.17
Age 0.00 0.88 to 0.91 0.00 0.04 to 0.05
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the second patient, elevated total fasting serum bile acid levels
were documented with 53.0 mmol/l (reference 0e7.9 mmol/l).
One clinically relevant cholangitis episode requiring antibiotic
treatment was recorded but no emergency endoscopic retrograde
cholangiography was required in any of the patients during
pregnancy. However, in one patient with cirrhosis who had been
repeatedly treated with endoscopic balloon dilatation before
pregnancy, dilatation of a dominant stenosis had to be
performed within two months after delivery due to rising serum
bilirubin levels. Liver enzymes improved in only 8% of cases
during pregnancy.
Pruritus is common both in PSC and in pregnancy. Patients
reported pruritus before pregnancy in five cases and in two of
these, pruritus improved during pregnancy. Two patients
developed pruritus de novo during pregnancy, of which one may
have been related to the onset of ICP and another one appeared
after discontinuation of UDCA treatment and improved after
reintroduction of the drug. Patients complained of worsening
pruritus post-partum in three cases and in one case this led to an
increase in UDCA dosage as compared to the pre-conceptional
dosage.
Only one flare of ulcerative colitis was recorded during preg-
nancy and none post-partum.
Pregnancy outcome
The 25 recorded pregnancies resulted in 21 live births with
a median birth weight of 3200 g (range 1694e4075 g, table 5).
Delivery was in the 39th week of gestation (range 31e41). All of
the 21 live births had a normal perinatal development with
a median APGAR score of 10 (range 7e10). The children devel-
oped normally over a median observation time of 50 months
(range 3e132). Two pregnancies resulted in pre-term delivery
before the 36th week of gestation due to ICP and pre-term
ruptured membranes, respectively. Seven of the 21 children were
delivered via caesarian section and one vacuum extraction had to
be performed. No serious complications were reported for the
other 13 vaginal deliveries.
Adverse pregnancy outcomes
Four of the 25 pregnancies ended with a spontaneous pregnancy
loss, giving a fetal loss rate of 16% (table 5). The median
gestational week at the time of pregnancy loss was the 8th week
(range 6the11th week): fetal loss was not associated with an
advanced stage of maternal disease. Two pregnancy losses
Table 3 Characteristics of patients with PSC and
pregnancy
Patients, n 17
Median age at conception, years (range) 31 (22e37)
Pregnancies, n 25
Patients with cirrhosis, n (%) 2 (12)
Inflammatory bowel disease, n (%) 14 (82)
Ulcerative colitis, n (%) 10 (59)
Crohn’s disease, n (%) 3 (18)
Indeterminate colitis, n (%) 1 (6)
Autoimmune hepatitis overlap, n (%) 2 (12)
Table 4 Maternal outcome in 17 PSC patients with 25 pregnancies
n %
Maternal death or liver transplantation 0 0
Biochemical activity
Increase in liver enzymes during pregnancy 5 20
Increase in liver enzymes post-partum 8 32
IBD activity (n[14 with IBD)
Flare during pregnancy 1 7
Flare post-partum 0 0
Pruritus
Before pregnancy 5 20
During pregnancy 7 28
Post-partum 4 16
Figure 1 Serum liver tests before, during and after pregnancy in
patients with PSC.
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occurred after stopping UDCA/azathioprine treatment. For the
other two, no associated event could be elucidated.
Medical treatment during pregnancy and its effect on
maternal and fetal outcome
The influence of medication on maternal and fetal outcome was
investigated. Details on medication and on the effect of UDCA
on fetal outcome are given in tables 6 and 7. UDCA was not
applied during eight pregnancies. In two of these cases UDCA
had not been introduced before pregnancy, in one case it was
stopped after recognition of pregnancy at week 4, and in five
cases UDCA was stopped due to planned conception. During
nine pregnancies, UDCA treatment was continued throughout
all three trimesters, and in eight pregnancies it was re-adminis-
tered after the first trimester. The median dose of UDCA during
pregnancy was 1000 mg per day (range 500e1500 mg) at
a weight-based dosage of 16 mg/kg/d (8e21 mg/kg/d).
Treatment with UDCA during pregnancy did not seem to
affect fetal outcome. However, in patients on UDCA treatment,
liver enzymes remained stable more often compared to patients
not receiving UDCA during pregnancy (increase to more than
twice the pre-conceptional value: (13% vs 67%, p¼0.049)).
In four cases, azathioprine had been stopped before concep-
tion due to planned pregnancy. During two pregnancies
azathioprine at a dose of 75 mg per day was continued perma-
nently and in another one it was re-administered after the first
trimester. All three had a beneficial pregnancy outcome.
DISCUSSION
In autoimmune and immune-mediated diseases such as auto-
immune hepatitis or systemic lupus erythematosus, pregnancy
may significantly affect the course of disease.3e7 Several lines of
evidence including recent genome-wide association studies
support the notion that PSC has properties of both, an auto-
immune and immune-mediated disease of the liver and bile
ducts.8e10 Our assessment of the rate and outcome of preg-
nancies in a cohort of pregnant PSC patients revealed no
differences to normal controls. Pregnancy in patients with PSC
frequently caused a rise in serum liver tests but did not cause
serious maternal complications.
Female sex hormones are known to modulate cellular and
humoural immune functions including the cytokine profile and
a state of tolerance may predominate during pregnancy.7 18
Consistently, in autoimmune hepatitis remissions occur during
pregnancy and flares can be observed in up to 50% after
delivery,3e7 whereas in IBD the influence of pregnancy and
delivery on the activity of disease is less pronounced.19
Assessing disease activity in patients with PSC is difficult. We
here report the rate of serum liver tests increasing to more than
twice the pre-pregnancy values. Clearly, this is a rather crude
method that may not reflect histological activity or indicate
disease progression. Differentiation from episodes of bacterial
cholangitis may also be difficult. Serum liver tests increased
markedly in 20% during pregnancy and in 32% within the first
3 months post-partum. One patient presented with de novo PSC
after delivery. These numbers are within the reported range for
patients with autoimmune hepatitis and may support the
notion that PSC is at least an immune-mediated disease of the
liver.
Despite the frequent rise in serum liver tests, no serious
maternal complications were recorded during pregnancy or after
delivery and, notably, no emergency endoscopic treatment had
to be performed during pregnancy. This stands in contrast to
patients with autoimmune hepatitis, in whomeprobably due to
a higher rate of liver cirrhosis and immunosuppressione
maternal complications are of concern and may even result in
maternal death.3 4 6 Of note, in this series only two patients had
known liver cirrhosis, which may contribute to the low
complication rate reported. In the Swedish series reported
before, 4 of 10 patients had liver cirrhosis and the course of
disease did not seem to be affected by pregnancy.11 From the
limited data available one could therefore conclude that preg-
nancy in PSC seems to be safe for the mother, at least unless
advanced liver cirrhosis is present.
With regard to symptoms, pruritus was the most prominent
complaint which occurred during seven pregnancies. Of three
cases with worsening pruritus during the last trimester of preg-
nancy, two were suspected as suffering from ICP by the consul-
ting hepatologists. ICP generally occurs in late pregnancy with an
estimated prevalence of 1/1000.20 In 2 of the 10 Swedish PSC
patients with pregnancy, pruritus was so intense as to bring on
premature delivery, a typical complication of ICP.11 Therefore it
may be tempting to speculate on overlapping features of pruritus
in PSC and ICP and a potentially increased prevalence of ICP
in pregnant patients with PSC. ICP and PSC may share common
genetic traits such as polymorphisms within the ABCB4
gene.21 22 UDCA has been established as the treatment of choice
for ICP.23 In the Swedish series,11 none of the patients had been
treated with UDCA. In many European countries, patients with
PSC are treated with UDCA and the patients described within
this paper were treated before the data on potentially harmful
effects of UDCA in patients with advanced disease emerged.16
Although beneficial effects of UDCA on the progression of PSC
Table 5 Fetal outcome of 25 pregnancies in 17 patients with PSC
Median Range
Week of gestation (wk) 39 31e41
Size at birth (cm) 50 46e56
Weight at birth (g) 3200 1694e4075
Perinatal developmental status (APGAR) 10 7e10
Follow-up period (months) 50 3e132
n %
Live births 21 84
Normal long-term development of children 21 100
Fetal losses 4 16
Pre-term deliveries 2 10







Before pregnancy 6 (24) 21 (84) 6 (24)
During complete pregnancy 2 (8) 9 (36) 4 (16)
After first trimester 3 (12) 17 (68) 4 (16)
Post-partum 3 (12) 23 (92) 5 (20)
Table 7 Influence of UDCA treatment during pregnancy
on fetal outcome
No UDCA (n[8) UDCA (n[17)
n (%) n (%)
Pregnancies 8 (32) 17 (68)
Fetal outcome
Live births 6 (75) 15 (88)
Fetal losses 2 (25) 2 (12)
Pre-term delivery 1 (13) 1 (6)
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have not been shown to date and high-dose UDCA should not
be applied,2 16 moderate doses of UDCA may be tried in the
treatment of pregnant PSC patients with pruritus.
The number of children was not different between the PSC
patients and healthy controls analysed. As doctors may be
reluctant to prescribe hormonal contraception to their patients
with PSC, this potential bias may lead to an overestimation of
the number of children in the PSC group as compared to the
healthy control group. Unfortunately, information on the
potential use and type of contraception was not available from
the PopGen database. Therefore, the conclusion that fertility is
not reduced in patients with PSC must be interpreted with
caution.
UDCA treatment is presumed to be safe during the second
and third trimester and may be safe earlier in pregnancy
although formal approval is lacking in most countries. In the
series reported here, UDCA was administered continuously
during eight pregnancies, and was re-administered in another
eight pregnancies after the first trimester. A negative impact on
fetal outcome was not detected.
The number of pregnancies exposed to azathioprine reported
here is too low to draw any conclusions. Of note however is that
two of the four fetal losses occurred after having stopped
azathioprine and UDCA treatment after the detection of
pregnancy. Experience from solid organ transplantation and
IBD patients suggests that the teratogenic potential of azathi-
oprine is outweighed by the beneficial effects of controlling
disease.19 24 Therefore it seems justified to continue low-dose
treatment with azathioprine in pregnant patients with PSC and
associated IBD.
Fetal loss rates of up to 30% have been reported in patients
with autoimmune hepatitis3 4 6 and comparable rates can be
found in other autoimmune diseases, such as type I diabetes
mellitus.25 We here report a fetal loss rate of 16%, which overall
seems to be similar to the rates reported for autoimmune
hepatitis and for the general US population.26 Fetal loss in our
series did not seem to be related to the severity of liver disease.
However, all patients with fetal loss had concomitant IBD.
Active IBD has been associated with miscarriage, stillbirth,
prematurity and low birth weight.19 Correspondingly, in one of
our patients two fetal losses occurred in the presence of active
ulcerative colitis. Together with the positive fetal outcome
reported before, these numbers may indicate that PSC does not
bear an increased risk of fetal loss by itself.
In conclusion, fertility does not seem to be reduced in PSC. We
here report from the largest series of patients with PSC and
pregnancy available to date, that successful pregnancies can be
achieved by patients with PSC. No impairment of fetal outcome
and no serious maternal complications were recorded. Pruritus is
common in late pregnancy and the potential clinical and genetic
overlap with ICP may warrant further study.
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